Compare TSHA & DCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSHA | DCO |
|---|---|---|
| Founded | 2019 | 1849 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2020 | N/A |
| Metric | TSHA | DCO |
|---|---|---|
| Price | $5.48 | $92.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $10.22 | ★ $117.80 |
| AVG Volume (30 Days) | ★ 3.8M | 97.6K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $6,310,000.00 | ★ $806,224,000.00 |
| Revenue This Year | N/A | $6.10 |
| Revenue Next Year | N/A | $8.13 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 3.17 |
| 52 Week Low | $1.05 | $51.76 |
| 52 Week High | $5.95 | $101.47 |
| Indicator | TSHA | DCO |
|---|---|---|
| Relative Strength Index (RSI) | 59.06 | 51.02 |
| Support Level | $5.22 | $91.51 |
| Resistance Level | $5.95 | $98.45 |
| Average True Range (ATR) | 0.34 | 2.92 |
| MACD | 0.05 | 0.31 |
| Stochastic Oscillator | 75.26 | 37.38 |
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers and manufactures various sizes of complex contoured aerostructure components and assemblies and supplies composite and metal bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in technology-driven markets including A&D and Industrial end-use markets. It generates maximum of its revenue from the Electronic Systems.